Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis (CROSBI ID 307313)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Lucijanic, Marko ; Galusic, Davor ; Krecak, Ivan ; Sedinic, Martina ; Soric, Ena ; Holik, Hrvoje ; Perisa, Vlatka ; Moric Peric, Martina ; Zekanovic, Ivan ; Stoos-Veic, Tajana et al. C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis // Leukemia & lymphoma, 61 (2020), 12; 2969-2974. doi: 10.1080/10428194.2020.1789627

Podaci o odgovornosti

Lucijanic, Marko ; Galusic, Davor ; Krecak, Ivan ; Sedinic, Martina ; Soric, Ena ; Holik, Hrvoje ; Perisa, Vlatka ; Moric Peric, Martina ; Zekanovic, Ivan ; Stoos-Veic, Tajana ; Kusec, Rajko

engleski

C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis

We retrospectively investigated C reactive protein to albumin ratio (CAR) in a cohort of 142 patients with myelofibrosis [101 primary (PMF) ; 41 secondary (SMF)] and compared it to hematological and clinical parameters. Among other associations, higher CAR was significantly associated with higher grade of bone marrow fibrosis, lower frequency of Calreticulin (CALR) mutations, presence of constitutional symptoms, massive splenomegaly, transfusion dependency, blast phase disease, lower hemoglobin, lower platelets, higher ferritin and higher lactate dehydrogenase (LDH) (p < .05 for all analyses). Higher CAR was able to predict inferior survival in PMF independently of DIPSS [hazard ratio (HR)¼2.17 ; p ¼ .015 for high CAR and HR¼ 2.05 ; p < .001 for DIPSS] and in SMF independently of Mysec-PM (HR¼ 6.48 ; p ¼ .022 for high CAR and HR¼ 2.63 ; p ¼ .013 for Mysec-PM) demonstrating its good prognostic potential. CAR seems to be an independent and prognostically relevant parameter, both in PMF and SMF, and might aid in timely recognition of most vulnerable patients.

Myeloproliferative neoplasm ; myelofibrosis ; C reactive protein ; albumin ; survival

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

61 (12)

2020.

2969-2974

objavljeno

1042-8194

1029-2403

10.1080/10428194.2020.1789627

Povezanost rada

nije evidentirano

Poveznice
Indeksiranost